Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor

Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluis Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen, José Baselga

Research output: Contribution to journalArticlepeer-review

Abstract

A subgroup of human epidermal growth factor receptor 2 (HER2)-overexpressing breast tumors coexpresses p95HER2, a truncated HER2 receptor that retains a highly functional HER2 kinase domain but lacks the extracellular domain and results in intrinsic trastuzumab resistance. We hypothesized that lapatinib, a HER2 tyrosine kinase inhibitor, would be active in these tumors. We have studied the correlation between p95HER2 expression and response to lapatinib, both in preclinical models and in the clinical setting.
Original languageEnglish
Pages (from-to)2688-95
Number of pages8
JournalClinical Cancer Research
Volume16
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor'. Together they form a unique fingerprint.

Cite this